Literature DB >> 7171839

Variability of steroid receptors in multiple biopsies of breast cancer: effect of systemic therapy.

Y T Lee.   

Abstract

Estrogen receptor (ER) was measured on two or more specimens taken from each of 53 patients with carcinoma of the breast (18 also had progesterone receptor analyzed). Among the 35 patients who had no interval therapy, 27 patients had repeated tests within one month, and only two had reversal of ER results. Among the eight patients who had ER tests 9-36 months apart, four of five ER + lesions (7 + fmol/mg cytosol protein) had ER - metastasis. Among the 18 patients who received systemic therapy, three of ten ER + became ER -, while two of ten ER - became ER +. Our data and reports in the literature are summarized, showing that about 20% of receptor studies among multiple samples are different even when patients received no interval therapy. In asynchronous studies, it is more likely to have ER positive change to negative than vice versa (31% vs 12%). Interval chemotherapy or endocrine therapy tends to increase the occurrence of ER negative relapse among patients with ER positive tumors.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7171839     DOI: 10.1007/bf01806455

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  29 in total

1.  Malignant and benign human mammary disease: estrogen binding in relation to clinical data.

Authors:  L Terenius; H Johansson; A Rimsten; L Thorén
Journal:  Cancer       Date:  1974-05       Impact factor: 6.860

2.  Increased incidence of positive tests for estrogen binding in mammary carcinoma specimens transported in liquid nitrogen.

Authors:  F Muschenheim; J L Furst; H A Bates
Journal:  Am J Clin Pathol       Date:  1978-11       Impact factor: 2.493

3.  Sampling procedures in estrogen receptor determinations.

Authors:  J F Newsome; F P Avis; J E Hammond; S Sherwood
Journal:  Ann Surg       Date:  1981-05       Impact factor: 12.969

4.  Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication.

Authors:  J S Meyer; B R Rao; S C Stevens; W L White
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

Review 5.  Current status of estrogen and progesterone receptors in breast cancer.

Authors:  W L McGuire; K B Horwitz; O H Pearson; A Segaloff
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

6.  Analysis of estradiol and progesterone receptors in early and advanced breast tumors.

Authors:  R J King
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

7.  The variability of estrogen receptors in metastatic breast cancer.

Authors:  M J Brennan; W L Donegan; D E Appleby
Journal:  Am J Surg       Date:  1979-02       Impact factor: 2.565

8.  Association between estrogen receptors and weight in women with breast cancer.

Authors:  A E Papatestas; D Panveliwalla; D Pertsemlidis; M Mulvihill; A H Aufses
Journal:  J Surg Oncol       Date:  1980       Impact factor: 3.454

9.  Relationship of steroid receptor, cell kinetics, and clinical status in patients with breast cancer.

Authors:  T E Kute; H B Muss; D Anderson; K Crumb; B Miller; D Burns; L A Dube
Journal:  Cancer Res       Date:  1981-09       Impact factor: 12.701

10.  Estrogen and progesterone receptors in breast carcinoma: correlations with epidemiology and pathology.

Authors:  M L Lesser; P P Rosen; R T Senie; K Duthie; C Menendez-Botet; M K Schwartz
Journal:  Cancer       Date:  1981-07-15       Impact factor: 6.860

View more
  2 in total

Review 1.  Patterns of metastasis and natural courses of breast carcinoma.

Authors:  Y T Lee
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

2.  Simultaneous and sequential determinations of steroid hormone receptors in human breast cancer. Influence of intervening therapy.

Authors:  R Jakesz; C Dittrich; J Hanusch; R Kolb; R Lenzhofer; K Moser; H Rainer; G Reiner; M Schemper; J Spona
Journal:  Ann Surg       Date:  1985-03       Impact factor: 12.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.